Archive for the ‘Gene Therapy Research’ Category

Implementation of Genetic Medicine Programs: Laboratories - Stephen Chanok
June 28-29, 2012 - Sequencing in Cohort Studies and Large Sample Collections More: http://www.genome.govFrom:GenomeTVViews:30 1ratingsTime:20:54More inScience Technology

Follow this link:
Implementation of Genetic Medicine Programs: Laboratories - Stephen Chanok - Video

3D Printing: The Future of Manufacturing
Alex Daley of Casey Research discusses the 3D printing revolution and its impact on the future of manufacturing. He also sheds light on curing cancer, biological medicine, genetic medicine, digital content, computer technology, electronic devices, popular mechanics, the human genome, globalization, monoclonal antibodies, biotechnology and much more. Michael Nuschke, author of Retirement Singularity, discusses the technology and science behind 3D printing 3D manufacturing and how this will impact investors. ****************************************** Original source: http://www.youtube.com Blog: http://www.RetirementSingularity.com Facebook http://www.facebook.com Twitter: twitter.com Google+: plus.google.comFrom:RetireSingularityViews:318 9ratingsTime:09:25More inEducation

See more here:
3D Printing: The Future of Manufacturing - Video

Shane McKee: Showreel 1
Never let Shane out in Israel with an iPhone. This is a showreel I put together for PastPreservers, purely from footage hand-shot with an iPhone, and some photos audio patched in. I #39;m a Clinical Geneticist (doctor in Genetic Medicine), so that #39;s the area I can claim proper expertise in, but my other science communication interests include: the Middle East (ancient and modern), Egyptology, General Science, the Religion-Science debate, Human Origins and lots more.From:Shane McKeeViews:47 1ratingsTime:04:54More inEducation

The rest is here:
Shane McKee: Showreel 1 - Video

Richard Morimoto, 2nd International Conference «Genetics of Aging and Longevity»
Richard Morimoto (Northwestern Center for Genetic Medicine, USA) "The stress of misfolded proteins in biology, aging and disease".From: #1060; #1086; #1085; #1076; #1059; #1052; #1040;Views:4 0ratingsTime:37:27More inScience Technology

Read the rest here:
Richard Morimoto, 2nd International Conference «Genetics of Aging and Longevity» - Video

Update on Down Syndrome Research: A Collaboration Between DSRTF and NDSS
In celebration of October 2012 as Down Syndrome Awareness Month, the National Down Syndrome Society and the Down Syndrome Research and Treatment Foundation collaborated with Dr. Roger Reeves to update the Down syndrome community on the status of Down syndrome cognition research. Dr. Roger Reeves is Professor in the Department of Physiology and a Core Faculty Member of the McKusick-Nathans Institute for Genetic Medicine at the Johns Hopkins University School of Medicine. He is noted for his contributions to the study of genes using animal models to understand to identify genetic modifiers that contribute to more or less severe presentation of Down syndrome. Slides from the presentation are available at http://www.ndss.orgFrom:NDSSorgViews:292 0ratingsTime:58:16More inNonprofits Activism

Read the rest here:
Update on Down Syndrome Research: A Collaboration Between DSRTF and NDSS - Video

October 31, 2012

Image Caption: A Selkirk Rex cat. Credit: Vetmeduni Vienna/Filler

April Flowers for redOrbit.com Your Universe Online

Appearance plays a large part in choosing a mate, whether that is your human spouse or your animal pet. Many human societies place a high value on curly hair for appearance as generations of perm-offering hair dressers can attest. It should be no surprise that pet owners and breeders are attracted to curly haired animals more frequently.

Three curly-haired varieties have been recognized and developed into competitive breeds already. A new study from the University of Veterinary Medicine, Vienna, describes a fourth curly haired breed, the Selkirk Rex, as genetically distinct from previously known breeds. Published in the Journal of Heredity, the study presents a genetic analysis of this unusual feline.

The history of the breed starts in Montana. A domestic cat rescued from a shelter in 1987 gave birth to a curly haired kitten. This kitten mated with a Persian male and gave birth to a mixed litter of curly and straight haired kittens, strongly suggesting that the mutation for curly hair in the original rescued cat is dominant. The presence of the mutation on one of the two copies of the gene involved is sufficient to cause cats to have curly hair. The curly haired Persian mix kittens were attractive and soon recognized as a new breed: the Selkirk Rex.

Extremely popular, the Selkirk Rex can be found at breeders worldwide. Even with this popularity, there had been no attempt to characterize the mutation responsible for the curly hair. Serina Filler of the University of Veterinary Medicine, along with colleagues from the University of California, Davis and Agrobiogen, has investigated the new breed to present an initial description of the underlying genetic mechanism.

The mutation is dominant, meaning Selkirk Rex cats could be either homozygous carrying two copies of the mutation or heterozygous carrying only one copy of the mutation and one normal copy of the gene. Heterozygous Selkirk Rex cats are more popular. They present rounded ears, a more rounded head and a fully curled coat, which all conform to the written standard for the breed. Homozygous cats, on the other hand, tend to lose a large amount of hair when young. They do not show bald areas of skin, however.

Filler and her team investigated the pattern of inheritance for these traits. They examined the DNA for nearly 150 cats and were able to show that the gene mutated in Selkirk Rex is distinct from mutations in other recognized breeds. They named this mutation Selkirk Autosomal Dominant Rex, or SADRE. An analysis of the 20 available pedigrees suggests that the original mutation presented approximately 8 or 9 generations ago, fitting in with the breeds known history.

Cross breeding in cats is very closely controlled. It is permitted to cross Selkirk Rex with a variety of other breeds, including Persians, Exotic Shorthairs, British Shorthairs, and British Longhairs. This crossbreeding makes the Selkirk Rex a genetically diverse breed with a low coefficient of inbreeding. The breed seems to be closely related to both Persian and British Shorthairs, probably reflecting the frequency with which they are crossbred. The British Shorthair influence seems more pronounced and is consistent with the overall body shape of the Selkirk Rex.

Originally posted here:
Genetic Analysis Of Unusually Curly Haired Selkirk Rex Completed

Public release date: 31-Oct-2012 [ | E-mail | Share ]

Contact: Haley Bridger hbridger@broadinstitute.org 617-714-7968 Broad Institute of MIT and Harvard

Crohn's disease (CD) and ulcerative colitis (UC) inflammatory diseases of the gastrointestinal tract have puzzled the scientific community for decades. Ten years ago, researchers recognized that both genes and the environment contributed to these diseases but knew little about precisely how and why illness occurred. To begin to narrow in on the key pathways involved, they would need thousands of patients' samples, millions of data points, and the commitment of physicians and scientists at dozens of institutions.

Today, researchers from across the CD and UC communities have come together to share raw data as well as newly collected genetic information to dissect the biology of a group of conditions that affects millions of people worldwide. Their research centers on the two diseases, which are collectively known as inflammatory bowel disease (IBD) and suggests a fundamental connection between risk of IBD and genes involved in other immune-related diseases and the immune system's response to pathogens. The work by researchers from the Broad Institute, Massachusetts General Hospital, Yale School of Medicine, Cedars-Sinai Medical Center, and dozens of other organizations appears in a Nature paper this week.

"This study marks the first time we've acquired and combined the raw data from so many research studies around the world and also the first time we've jointly analyzed Crohn's with ulcerative colitis," said author Mark Daly, one of the senior authors of the work and senior associate member of the Broad Institute and co-director of its Program in Medical and Population Genetics. Daly is also chief of the Analytic and Translational Genetics Unit at Massachusetts General Hospital (MGH) and an associate professor at Harvard Medical School. "We've been able, with this study, to evaluate the evidence for both diseases simultaneously, and discovered that the majority of genetic risk factors are associated with both diseases."

"There's been a paradigm shift in our understanding of IBD. This gene discovery process offers an opportunity to begin identifying new targets for treatment, better diagnostic tools, and in the long-term, personalized care for patients," said co-author Ramnik Xavier, a senior associate member of the Broad Institute, Chief of Gastroenterology and Director of the Center for the Study of Inflammatory Bowel Disease at MGH. "We now have the necessary starting material to understand the pathways that contribute to Crohn's disease and ulcerative colitis, and we also have a framework to better appreciate that they may not be two distinct diseases, but rather collections of many different diseases."

Crohn's disease (CD) and ulcerative colitis (UC) share much in common both cause many of the same gastrointestinal symptoms and both are marked by an improper response by the body's immune system to harmless cells or bacteria. Over the last ten years, researchers have performed genome-wide association studies, looking across the genomes of thousands of patients with either CD or UC and compared them to genomes from people without these diseases to find significant genetic differences. The new study not only brings together the original data from those previous analyses, but also adds genetic information from another 40,000 people either with or without a form of IBD.

"If we want to get more hits but also dissect the differences between Crohn's disease and ulcerative colitis or understand the commonalities, we really need to share all of our genetic data," said co-first author Stephan Ripke, a researcher at the Broad Institute and MGH. Ripke worked closely with co-first author Luke Jostins of the Sanger Institute to combine and then analyze genetic information collected by researchers from many different institutions.

The new study identified 71 additional genetic associations for IBD, many of which have been previously implicated in other immune-related disorders, including ankylosing spondylitis and psoriasis. The new research also suggests a strong overlap between IBD susceptibility genes and genes tied to the immune system's response to mycobacterial infections, including tuberculosis and leprosy. Researchers have observed similarities between the immune response in CD and that seen in tuberculosis and hypothesize that CD could be an aberrant response to certain harmless organisms present in the gut that trigger a similar reaction.

In addition to drawing upon original data from previous studies, the work utilizes a relatively new tool known as the immunochip, which samples 200,000 sites in the genome previously tied to autoimmune and inflammatory diseases.

The rest is here:
New genetic links for inflammatory bowel disease uncovered

ScienceDaily (Oct. 31, 2012) Completing the second phase of the 1000 Genomes Project, a multinational team of scientists reports that they have sampled a total of 1092 individuals from 14 different populations and sequenced their full genomes. The researchers described the feat as a collegial effort to equip biologists and physicians with information that can be used to understand the normal range of human genetic variants so that a patient's disease genome can be interpreted in a broader context.

A report on the research, published online in Nature on Nov. 1 represents the culmination of five years of work, says Aravinda Chakravarti, Ph.D., professor of medicine and pediatrics and a member of the Institute of Genetic Medicine at the Johns Hopkins School of Medicine. Chakravarti helped to design the population genetics sampling plan.

"The DNA donors in the study were not known to have any diseases, so the study gives us the genomic background we need for understanding which genetic variations are 'within the normal range,'" Chakravarti says. "With this tool, scientists now have a standard with which they can compare the genome of someone with diabetes, for example." That in turn, Chakravarti says, will increase opportunities for understanding the disease and creating targeted, individualized treatment.

The selection of the 14 populations sampled was based on their ancient migratory history and their genetic relationship to the other populations studied. Within each population, healthy, unrelated donors were randomly chosen for blood draws. The blood samples were first transformed into cell lines that can be stored and grown indefinitely so that they will always be available for future studies. After cell lines were grown, the DNA was sequenced and added to a public database.

The first human genome to be sequenced, published in 2003, made clear that as much as 98.5 percent of human genetic material does not encode proteins, as had been thought. Scientists now know the role of some of the non-protein-coding regions and, although much of the genome remains a mystery, there is reason to suspect that at least some of it plays a part in the variability seen in disease susceptibility and prevalence.

"The 1000 Genomes Project started at the beginning, with the whole genome and with no bias in the search for disease-related variants toward protein-coding genes," Chakravarti explains. "Regulatory sequences and sequences we still don't understand were also catalogued, so this information widens the areas of the genome we can search when looking for disease-causing variants." Most of the genetics research done to date has begun with a disease or a protein that is known to be malfunctioning, followed by a hunt for the responsible genetic variants.

The genetic variations found in the populations analyzed were categorized by how frequently they appeared in the individuals tested. Variants seen in more than five percent of the samples were classified as common variants, while low-frequency variants appeared in 0.5 to five percent of individuals and rare variants in less than 0.5 percent of the samples.

The 14 populations sampled were divided into four ancestry groups: European, African, East Asian and American. As expected, most of the common variants had already been identified in previous studies, and their frequencies varied little between ancestry groups.

By contrast, 58 percent of the low-frequency variants and 87 percent of the rare variants were described for the first time in this study. Rare variants were sometimes twice as likely to be found within a particular population as in that population's broader ancestry group. Different populations also showed different numbers of rare variants, with the Spanish, Finnish and African-American populations carrying the greatest number of them.

Amazingly, Chakravarti says, the researchers found that among rare variants, the healthy people in their study possessed as many as 130 to 400 protein-altering variants; 10 to 20 variants that destroy the function of the proteins they encode; two to five variants that damage protein function; and one or two variants associated with cancer. The implication is that all healthy people everywhere carry similar numbers of rare, deleterious variants.

Read more:
1092 human genomes sequenced to determine standard range of human genetic variation

BUDAPEST, HUNGARY--(Marketwire - Oct 22, 2012) - Genetic Immunity ( OTCBB : PWRV ), a leader in immunotherapy technology, announced the peer-reviewed publication on the Company's groundbreaking nanotechnology and details on its potential for the cure of HIV. The manuscript is entitled "Nanomedicine applications Towards the Cure of HIV" by J. Lisziewicz and E. R. Toke (http://www.nanomedjournal.com/article/S1549-9634(12)00287-0/abstract).

The Scientists of Genetic Immunity pioneered research for the cure of HIV: in 1999 they described in the New England Journal of Medicine the first patients whose immune system was boosted to control HIV after interruption of his daily drug treatment (http://www.nejm.org/doi/full/10.1056/NEJM199905273402114). This observation inspired development of a new medicine called DermaVir that boosts the immune system to specifically recognize and kill HIV infected cells. Today, DermaVir is the most advanced nanomedicine developed for the cure of HIV.

"We have about 30 potent HIV drugs suppressing viral load, but we do not have any to eliminate the infected cells from the reservoirs. To cure HIV we need new drugs to activate these infected cells and to kill them. In our manuscript we described the new drugs that are needed and the strategy that will result in the cure of HIV. One of these new essential drugs for HIV eradication is DermaVir, our lead HIV-specific immunotherapeutic product. In contrast to the daily oral drugs, DermaVir is administered a few times a year with four patches. Our Clinical Trials have shows DermaVir to be as safe as a placebo and it induced long-lasting HIV-specific T cell production. Our GIEU006 Phase II trial demonstrated significant killing of HIV-infected cells, producing 70% viral load reduction compared to a placebo. Our results suggest that DermaVir provides the immunologic drug component towards the eradication of HIV," said Dr. Julianna Lisziewicz, CEO of Genetic Immunity.

Eradication of HIV is a difficult goal to achieve, because a reservoir of HIV is established soon after infection and it persists even after years of potent antiretroviral treatment. New drugs under development can activate dormant HIV and flush the virus from the reservoirs. However, activation is not enough, HIV-infected cells must be detected and killed by the immune system. In Hepatitis C, which is caused by a virus transmitted through the blood similarly to HIV, the cure rate is up to 75% because the use of drugs that suppress virus replication and induce the immune system to fight the virus. Up to now the cure of HIV has not been achieved with drugs that suppress the virus. Therefore, DermaVir will be required to induce the immune system to fight HIV and contribute to the cure of HIV/AIDS.

Genetic Immunity is a wholly owned subsidiary of Power of the Dream Ventures, Inc. ( OTCBB : PWRV ).

About Genetic Immunity

Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures, Inc. ( OTCBB : PWRV ), is a clinical stage technology company committed to discovering, developing, manufacturing and commercializing a new class of immunotherapeutic biologic drugs for the treatment of viral infections, cancer and allergy. Our Langerhans cell targeting nanomedicines are exceptional in both safety and immune modulating activity boosting specific Th1-type central memory T cells. These are essential to eliminate infected cells or cancerous cells, and balance the immune reactivity in response to allergens.

In 1988 Drs. Lisziewicz and Lori founded Genetic Immunity in the US after they described the 1st patient whose immune system was boosted to control HIV after treatment interruption (Lisziewicz et al. New England Journal of Medicine 1999) that lead to the invention of DermaVir. The Company's innovative technology team directed by Dr. Lisziewicz, a champion of immune boosting therapies, is now headquartered in Budapest, Hungary. She has been invited into the Scientific Advisory Board of the HIV Cure Initiative led by Francoise Barre-Sinoussi, Nobel Prize Laureate for her HIV research in 2009. For more information please visit http://www.geneticimmunity.com

Read this article:
Genetic Immunity Publishes the Technology Roadmap for the Cure of HIV

By Ludwig Burger

FRANKFURT (Reuters) - Software engineers are moving to the fore in the war on cancer, designing programmes that sift genetic sequencing data at lightning speed and minimal cost to identify patterns in tumors that could lead to the next medical breakthrough.

Their analysis aims to pinpoint the mutations in our genetic code that drive cancers as diverse as breast, ovarian and bowel. The more precise their work is, the better the chance of developing an effective new drug.

Ever since James Watson and Francis Crick discovered the structure of DNA in 1953, scientists have been puzzling over how genes make us who we are. The confluence of computing and medicine is accelerating the pace of genetic research.

But making sense of the swathes of data has become a logjam.

That, in turn has created an opportunity for computer geeks and tech firms such as Microsoft, SAP and Amazon.

Oncology is the largest area of therapy in the global drugs market with market researcher IMS predicting it will increase to $83-$88 billion by 2016 from $62 billion in 2011. Computational genomics - using computers to decipher a person's genetic instructions and the mutations in cancerous cells - is emerging as the driver of this growth.

Life Technologies Corp and Illumina Inc are among firms developing equipment that can extract a person's entire genetic code - their genome - from a cell sample.

The newest machines are about the size of an office printer and can sequence a genome in a day, compared with six to eight weeks a few years ago. They can read the 3.2 billion chemical "bases" that make up the human genetic code for $1,000, compared with $100,000 dollars in 2008.

Growing numbers of software engineers are needed to help make sense of all this data.

Originally posted here:
Insight: Crunching the numbers to boost odds against cancer

Newswise By decoding the genomes of more than 1,000 people whose homelands stretch from Africa and Asia to Europe and the Americas, scientists have compiled the largest and most detailed catalog yet of human genetic variation. The massive resource will help medical researchers find the genetic roots of rare and common diseases in populations worldwide.

The 1000 Genomes Project involved some 200 scientists at Washington University School of Medicine in St. Louis and other institutions. Results detailing the DNA variations of individuals from 14 ethnic groups are published Oct. 31 in the journal Nature. Eventually, the initiative will involve 2,500 individuals from 26 populations.

With this resource, researchers have a roadmap to search for the genetic origins of diseases in populations around the globe, says one of the study's co-principal investigators, Elaine Mardis, PhD, co-director of The Genome Institute at Washington University. We estimate that each person carries up to several hundred rare DNA variants that could potentially contribute to disease. Now, scientists can investigate how detrimental particular rare variants are in different ethnic groups.

At the genetic level, any two people are more than 99 percent alike. But rare variants those that occur with a frequency of 1 percent or less in a population are thought to contribute to rare diseases as well as common conditions like cancer, heart disease and diabetes. Rare variants may also explain why some medications are not effective in certain people or cause side effects such as nausea, vomiting, insomnia and sometimes even heart problems or death.

Identifying rare variants across different populations is a major goal of the project. During the pilot phase of the effort, the researchers found that most rare variants differed from one population to another, and that they developed recently in human evolutionary history, after populations in Europe, Africa, Asia and the Americas diverged from a single group. The current study bears this out.

This information is crucial and will improve our interpretation of individual genomes, says another of the study's co-principal investigators, Richard K. Wilson, PhD, director of The Genome Institute and a pioneer in cancer genome sequencing. Now, if we want to study cancer in Mexican Americans or Japanese Americans, for example, we can do so in the context of their diverse geographic or ancestry-based genetic backgrounds.

Results of the new study are based on DNA sequencing of the following populations: Yoruba in Nigeria; Han Chinese in Beijing; Japanese in Tokyo; Utah residents with ancestry from northern and western Europe; Luhya in Kenya; people of African ancestry in the southwestern United States; Toscani in Italy; people of Mexican ancestry in Los Angeles; Southern Han Chinese in China; Iberian from Spain; British in England and Scotland; Finnish from Finland; Colombians in Columbia; and Puerto Rican in Puerto Rico.

All study participants submitted anonymous DNA samples and agreed to have their genetic data included in an online database. To catalog the variants, the researchers first sequenced the entire genome all the DNA of each individual in the study about five times. Surveying the genome in this way finds common DNA changes but misses many rare variants.

Then, to find rare variants, they repeatedly sequenced the small portion of the genome that contains genes about 80 times for each participant to ensure accuracy and they looked closely for single letter changes in the DNA sequence called SNPs (for single-nucleotide polymorphisms).

Using special tools developed to analyze and integrate the data, the researchers discovered a total of 38 million SNPs, including more than 99 percent of the variants with at frequency of at least one percent in the participants DNA samples. They also found numerous structural variations, including 1.4 million short stretches of insertions or deletions and 14,000 large DNA deletions.

Follow this link:
Global Genome Effort Seeks Genetic Roots of Disease

Public release date: 31-Oct-2012 [ | E-mail | Share ]

Contact: Mary Rice mary.rice@riceconseil.eu European Society of Human Genetics

In response to the on-line publication by the European Journal of Human Genetics today (Wednesday) of an article by US researchers led by Dr. Robert Cook-Degan, a former member of the US Office of Technology Assessment, showing that Myriad Genetics, providers of the BRCA1/2 genetic test in the US, has amassed vast quantities of clinical data without sharing it, Professor Martina Cornel, chair of the European Society of Human Genetics' Professional and Public Policy committee, said:

"We are very concerned that such important data is being withheld from those who most need it. Interpreting the variants of unknown significance (VUS) that may be found on analysing the patient's genome plays an essential part in being able to provide proper counselling and if necessary, preventive or therapeutic guidance. By not sharing their data on the VUS obtained from individuals undergoing BRCA1/2 testing, where Myriad is the sole commercial provider of a test in the US, geneticists have been unable to develop the up-to-date algorithms that are necessary to best interpret the effects of genetic variants. While Myriad has access to public databases in order to help interpret their VUS results, this is currently not reciprocal.

"We know that, regrettably, medical geographic inequities are common, but what is particularly worrying about this situation is that it is the first time that such inequities have been based on a lack of access to clinical information, rather than lack of a product. Myriad's stated aim to enter the European market more vigorously may lead to unfair competition with academic institutions for predictive precision. It is vital that progress towards personalised medicine, which holds out so much promise, is not hindered by companies maintaining private genomic databases. Policymakers should take an urgent look at the regulatory and reimbursement issues involved in genomic testing in order for all the data that is essential to understanding the clinical significance of VUS to be made public, to the benefit of patients and healthcare providers alike."

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Original post:
Privately owned genetic databases may hinder diagnosis and bar the way to the arrival of personalized medicine

Paleo Solution
Do you want stay young and look fit, and keep clear of heart disease, Parkinson #39;s, Alzheimer #39;s and a bunch of other disaeases? The Paleo Solution uses the latest research from genetics, to make sure you look, feel and perform your best. A research biochemist who traded in his lab coat and pocket protector became one of the most wanted strength and conditioning coaches in the world. With this unique perspective as both scientist and coach you will learn how simple nutrition, exercise and lifestyle changes can alter your health and appearance for the better.From:tabhol4Views:140 1ratingsTime:04:19More inNews Politics

View post:
Paleo Solution - Video

Hidden Source Episode 3 -Richard Has A Pussy-
Make sure to like and favorite this video, and feel free to subscribe for daily content. Give me feedback on how i can improve my videos or tells us what you would like to see, by leaving a comment! Twitch- http://www.twitch.tv Twitter- twitter.com Myself SouLxTRaPPeR playing some The Hidden Source! Nobody can see The Hidden only trained eyes can see him well! The objective of The Hidden Source is that the humans aka IRIS must eliminate The Hidden to win vice versa for the Hidden but as the title says he is invisible and only is equipped with a knife capable of a one hit kill depending on server and only three grenades. The hidden has many abilities like taunting, super strength to ram objects into IRIS soldiers or be able to leap super high and hang on buildings. Lastly The Hidden can heal himself by eating bodies but only if they are stabbed to death not PIGSTICKED! (which is the one hit kill move) The IRIS are equipped with four weapons ranging from shotgun to rifle to SMG and a few options of equipment like senors to laser optics on your gun. Game is The Hidden Source which requires Half life 2 engine meaning you have to have Half Life 2 purchased already or another source game to run with STORYLINE In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation ...From:SouLxTRaPPeRViews:1 1ratingsTime:07:54More inGaming

Go here to read the rest:
Hidden Source Episode 3 -Richard Has A Pussy- - Video

Chapter 9: The Molecular Biology of Translation (Part 1 of 4)
Texas Tech University Genetics Course student tutorial.From:NFHSdrummerViews:0 0ratingsTime:07:26More inEducation

See more here:
Chapter 9: The Molecular Biology of Translation (Part 1 of 4) - Video

In Treatment for Leukemia, Glimpses of the Future
ST. LOUIS mdash; Genetics researchers at Washington University, one of the world #39;s leading centers for work on the human genome, were devastated. Dr. Lukas Wartman, a young, talented and beloved colleague, had the very cancer he had devoted his career to studying. He was deteriorating fast. No known treatment could save him. And no one, to their knowledge, had ever investigated the complete genetic makeup of a cancer like his.From:daniel santosViews:0 0ratingsTime:00:15More inEntertainment

See the rest here:
In Treatment for Leukemia, Glimpses of the Future - Video

Chapter 9: The Molecular Biology of Translation (Part 3 of 4)
TTU GeneticsFrom:NFHSdrummerViews:0 0ratingsTime:10:01More inEducation

Read the original post:
Chapter 9: The Molecular Biology of Translation (Part 3 of 4) - Video

Chapter 9: The Molecular Biology of Translation (Part 2.5 of 4)
TTU GeneticsFrom:NFHSdrummerViews:0 0ratingsTime:05:36More inEducation

Here is the original post:
Chapter 9: The Molecular Biology of Translation (Part 2.5 of 4) - Video

mRNA Splicing: A Comedy
for our Genetics presentation. Good times.From:Stephanie RayViews:1 0ratingsTime:02:44More inEducation

Read this article:
mRNA Splicing: A Comedy - Video

Update on wild caught bluegill + feeding
Progress update on the wild caught bluegill. "On average, most wild caught fish are caught with nets in their native body of water. Once the fishermen return with the fish, they are often help in large holding vats. Depending on the exporter, they can be held for 1 week to 1 month or longer. The wild tropical fish are then prepared for shipment. Exporters then take the wild caught fish to the airport for shipping. The wild tropical fish are then sent to the local fish importers and distributors. One must be licensed as a tropical fish importer to receive packages from other countries. The fish are then received, unpacked, and put into holding tanks. The wild tropical fish will be held in the distributor #39;s tanks until they are ready to be shipped to local fish stores. As you can see, these wild caught fish go through a lot before they get to our tanks. Lets review: wild tropical fish are caught, packaged and held in native land, next they are packed and shipped overseas to your home country, next they are unpacked and held in a distributor #39;s local facility, then packaged and shipped again to your local fish store, followed by being held at the local fish store, and finally packed and sent home to your tropical fish tank. Now think about all the different water conditions these fish have been exposed to. This is why it is very important to ensure that you have excellent water conditions when you bring your new tropical fish home. Benefits of Wild Caught Fish: There are ...From:Bakedea87Views:0 0ratingsTime:06:33More inPets Animals

Continued here:
Update on wild caught bluegill + feeding - Video

Miranda kerr Named Esquire UK Sexiest Woman Alive
Miranda Kerr, reminding human beings everywhere of the professional benefits associated with having both inner/outer beauty and a highly unattainable lifestyle indebted to yoga, berries and winning the genetics lottery, has just been named as Esquire UK #39;s "sexiest woman alive". The ubiquitous Gunnedah beauty covers the new December issue of the UK men #39;s periodical, appearing in a NSFW David Slijper cover shoot in basically a jacket, high heels and underwear. Surprise! Hard as it is to believe though, our favourite part is the interview that comes with it. We especially like the bit where she talks about her past life as a koala. "I still like to climb the odd tree. Yeah, it #39;s fun! I like to climb. I find it very rewarding. You feel like you #39;re going somewhere," she explains. "I don #39;t like abseiling, though. I don #39;t like going down. I like going up. It is though! I got stuck up a tree when I was about seven, and my dad had to come and get the ladder to get me down. I loved to climb all the way up to the top. I must have been a koala in my past life."From:WorldNews365Views:3 0ratingsTime:01:44More inEntertainment

Read more here:
Miranda kerr Named Esquire UK Sexiest Woman Alive - Video

Lost Civilizations Races - Patrick Chouinard - Coast to Coast AM Classic
Date: 05-16-12 Host: George Noory Guests: Patrick Chouinard, Marc Zicree, Doug Drexler, Neil Johnson Independent researcher, Pat Chouinard, discussed his work investigating the myths and traditions of ancient civilizations, why he believes they were actually real, and how archaeological discoveries suggest there were different species of humans roaming the planet in the past. He refuted the popular paranormal theory that ancient legends about #39;gods #39; are actually references to aliens. On the contrary, Chouinard contended that these tales are factual and that advanced, god-like beings as well as monsters and dragons are "true in the truest sense of the word." Over the course of the evening, Chouinard also talked about Caucasian mummies discovered in China, ET artifacts on Mars, and his belief in a "cosmic God," which oversees all of the universe. Chouinard detailed the intriguing findings revealed by the discovery of an ancient species of human dubbed the #39;X-Woman of Siberia. #39; According to him, genome information gleaned from the bones showed that it possessed the capacity for high intelligence and was neither neanderthal nor homo sapien. Based on the genetics, Chouinard described them as giants, compared to their bipedal contemporaries, and said that they looked like a cross between modern humans and the progenitors of the neanderthals. He theorized that the Siberian discovery, as well as finds in the country of Georgia and the #39;hobbits #39; of Flores, suggest that the cradle ...From:C2CPlanetViews:6 0ratingsTime:02:32:52More inEducation

The rest is here:
Lost Civilizations

SAN DIEGO and CAMBRIDGE, Mass., Oct. 22, 2012 /PRNewswire/ -- Good Start Genetics, a leading and innovative molecular diagnostics company offering the new gold standard for genetic disease carrier screening, announced today that it has launched an expanded menu of testing services. The announcement, made at this week's annual meeting of the American Society for Reproductive Medicine (ASRM), means that Good Start Genetics' screening service, GoodStart Select, now offers state-of-the-art testing for all 23 of the diseases recommended in guidelines set by the major medical societies, including the American Congress of Obstetricians & Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG) and societies supporting the Ashkenazi Jewish population. Good Start's screening services centers on the revolutionary, next- generation DNA sequencing platform - which can detect far more disease-causing mutations than the older, genotyping-based platform - with the goal of providing the highest carrier detection rates possible.

(Logo: http://photos.prnewswire.com/prnh/20111012/NY84930LOGO )

In addition to its menu of pan-ethnic tests (e.g. cystic fibrosis, fragile X syndrome and spinal muscular atrophy), tests for hemoglobinopathies (sickle cell anemia, alpha thalassemia and beta thalassemia) and routine tests for the Ashkenazi Jewish population, Good Start now offers the following additional tests: dihydrolipoamide dehydrogenase deficiency, familial hyperinsulinism, glycogen storage disease type 1a, Joubert syndrome 2, maple syrup urine diseases type A/B, nemaline myopathy, Usher syndrome type 1F, Usher syndrome type III, and Walker-Warburg syndrome.

Good Start performs testing in its CAP- and CLIA-accredited, state-of-the-art laboratory facility located in Cambridge, MA, and has built a dedicated team of customer care specialists, genetic counselors and board certified medical geneticists to support patients and clinics. Good Start works closely with patients and their insurance providers to simplify the billing and payment process. In addition, as part of its mission to provide accurate, simple and responsible testing, Good Start has launched a new web site, which includes patient and physician-friendly tools that facilitate in the test selection process. (Good Start's test menu can be customized for each patient based on family history, patient ethnicity, or any other criteria the clinician deems important.)

"Reproductive healthcare professionals have long followed guideline recommendations for carrier screening for their patients planning pregnancy," said Michael Alper, M.D., Medical Director & Reproductive Endocrinologist, Boston IVF. "However, conventional screening methods have, to date, been limited by either their rigidity or the relatively small number of mutations that can be analyzed in a specific gene. Given recent advancements with the next-generation sequencing technology, we are pleased to be able to offer Good Start's technology to our patients in routine clinical practice."

"We are excited to make these additional tests available, and to meet the growing screening needs of new families and those wishing to start families," said Don Hardison, Good Start Genetics President and Chief Executive Officer. "And, using our next generation sequencing platform, we are already detecting mutations that other laboratories simply cannot. With this powerful technology, combined with our intense customer focus, we are confident we are delivering the best screening experience possible for patients and clinicians and, most importantly, critical information that can help increase a couple's chance of having a healthy baby. As a result, we expect that our sequencing-based approach to screening will continue to replace older, genotyping-based approaches and solidify our reputation as a leader in the carrier screening market."

BackgroundAccording to figures from the U.S. Human Genome Project, there are more than 6,000 known single-gene disorders, which in aggregate affect about 1 out of every 200 births.[1] National organizations, such as ACOG and ACMG, recommend that preconception and prenatal carrier screening be made available for couples for a numerous genetic disorders, so that healthcare providers and their patients can better understand the risks of the patient being a carrier of a genetic disorder, and, therefore, the risk of passing that gene or disease on to their offspring.

Routine genetic carrier screening has traditionally employed targeted mutation analysis technologies via 'genotyping' platforms, which, due to cost considerations, are designed to detect only a small number of the most common disease-causing mutations which are prevalent in only specific populations. The next-generation sequencing platform developed by Good Start Genetics, however, allows for a more comprehensive determination of carrier status in routine clinical practice because it is not limited to a small targeted mutation set and, therefore, can achieve high clinical sensitivities regardless of ethnicity.

About Good Start GeneticsGood Start Genetics is setting the new gold standard in carrier screening in routine clinical practice by making testing for the most comprehensive set of disease-causing mutations. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable, and affordable tests for all ACOG-and ACMG-recommended disorders. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results, and no longer have to compromise accuracy for price. For online information about Good Start Genetics, please visit http://www.goodstartgenetics.com.

These tests were developed and their performance characteristics determined by Good Start Genetics. They have not been cleared or approved by the U.S. Food and Drug Administration. However, the laboratory is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical testing and the tests have been analytically validated in accordance with CLIA standards. Good Start Genetics is both CLIA- and CAP-accredited.

Originally posted here:
Good Start Genetics® Announces The Expansion of its Next-Generation DNA Sequencing -Based Carrier Screening Service

Published: Oct. 30, 2012 at 8:07 PM

HINXTON, England, Oct. 30 (UPI) -- Scientists using DNA sequencing say they've uncovered a previously unknown period when the human population expanded rapidly in prehistory.

The sequencing of 36 complete Y chromosomes revealed this population explosion occurred 40,000 to 50,000 years ago, between the first expansion of modern humans out of Africa 60,000 to 70,000 ago and the Neolithic expansions of people in several parts of the world starting 10,000 years ago, Britain's Wellcome Trust Sangster Institute reported.

"We have always considered the expansion of humans out of Africa as being the largest population expansion of modern humans, but our research questions this theory," Wei Wei of the Sanger Institute and the West China University of Medical Sciences said.

"Now we've found a second wave of expansion that is much larger in terms of human population growth and occurred over a very short period, somewhere between 40,000 to 50,000 years ago."

One possible theory is that during the original out-of-Africa expansion, humans moved along the coastlines of the world, settling as they went.

Their origins and genetic makeup would make them suited to coastal life, but not to the demands of living inland.

"We think this second, previously unknown population boom, may have occurred as humans adapted to their new environment after the first out-of-Africa expansion," institute researcher Qasim Ayub said.

"It took them tens of thousands of years to adapt to the mountainous, forested surroundings on the inner continents. "However, once their genetic makeup was suited to these new environments, the population increased extremely rapidly as the groups traveled inland and took advantage of the abundance of space and food," Ayub said.

Read the original post:
Genetics suggest global human expansion

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that it will report its third quarter and year-to-date 2012 financial results on Wednesday, November 7, 2012, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Wednesday, November 7, 2012 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at http://www.seattlegenetics.com.

Read more:
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2012 Financial Results on November 7 ...